Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals Target Price
Analysts' 12-month price predictions for REGN.
Share Price
$573.38
Average Target Price
$660.50
15.2% upside
15.2% upside6 analysts in the last 4 months
High: $755 | Low: $580
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-08-04 | BMO Capital | $640 | 11.6% upside |  |
| 2025-08-01 | CitigroupGeoff Meacham | $650 | 13.4% upside | |
| 2025-08-01 | Wells FargoMohit Bansal | $580 | 1.2% upside | |
| 2025-07-11 | UBSTrung Huynh | $584 | 1.9% upside | |
| 2025-07-10 | Morgan StanleyTerence Flynn | $754 | 31.5% upside | |
| 2025-06-02 | Morgan StanleyTerence Flynn | $755 | 31.7% upside | |
| 2025-04-22 | Cantor FitzgeraldCarter Gould | $695 | 21.2% upside | |
| 2025-04-22 | Canaccord GenuityJohn Newman | $850 | 48.2% upside | |
| 2025-03-14 | BMO Capital | $903 | 57.5% upside | |
| 2024-11-01 | BMO CapitalEvan David Seigerman | $1,190 | 107.5% upside | |
| 2024-11-01 | Piper SandlerChristopher Raymond | $1,195 | 108.4% upside | |
| 2024-11-01 | Leerink PartnersAndrew Berens | $880 | 53.5% upside | |
| 2024-10-31 | Evercore ISICory Kasimov | $1,170 | 104.1% upside | |
| 2024-10-24 | Evercore ISICory Kasimov | $1,175 | 104.9% upside | |
| 2024-10-23 | Wells FargoMohit Bansal | $1,050 | 83.1% upside | |
| 2024-09-24 | Truist FinancialThomas Klee | $1,200 | 109.3% upside | |
| 2024-09-24 | Leerink PartnersDavid Risinger | $1,077 | 87.8% upside | |
| 2024-09-24 | Robert W. BairdBrian Skorney | $940 | 63.9% upside | |
| 2024-09-24 | Goldman SachsSalveen Richter | $1,292 | 125.3% upside | |
| 2024-09-12 | BMO CapitalEvan David Seigerman | $1,300 | 126.7% upside | |
| 2024-09-09 | RBC CapitalBrian Abrahams | $1,282 | 123.6% upside | |
| 2024-08-23 | Raymond JamesChristopher Raymond | $1,242 | 116.6% upside | |
| 2024-08-02 | Bank of America SecuritiesGeoff Meacham | $805 | 40.4% upside | |
| 2024-08-02 | RBC CapitalBrian Abrahams | $1,240 | 116.3% upside | |
| 2024-07-19 | Raymond JamesChristopher Raymond | $1,166 | 103.4% upside | |
| 2024-07-18 | GuggenheimYatin Suneja | $1,180 | 105.8% upside | |
| 2024-07-12 | UBSTrung Huynh | $1,250 | 118% upside | |
| 2024-07-11 | Morgan StanleyTerence Flynn | $1,182 | 106.1% upside | |
| 2024-06-25 | Argus ResearchJasper Hellweg | $1,170 | 104.1% upside | |
| 2024-06-13 | RBC CapitalBrian Abrahams | $1,299 | 126.6% upside | |
| 2024-06-12 | RBC CapitalBrian Abrahams | $1,229 | 114.3% upside | |
| 2024-06-04 | RBC CapitalBrian Abrahams | $1,200 | 109.3% upside | |
| 2024-06-03 | BMO CapitalEvan David Seigerman | $1,082 | 88.7% upside | |
| 2024-05-20 | Raymond JamesChristopher Raymond | $1,000 | 74.4% upside | |
| 2024-05-13 | Evercore ISICory Kasimov | $1,150 | 100.6% upside | |
| 2024-05-03 | RBC CapitalBrian Abrahams | $1,185 | 106.7% upside | |
| 2024-04-12 | JefferiesAkash Tewari | $1,060 | 84.9% upside | |
| 2024-04-11 | RBC CapitalBrian Abrahams | $1,189 | 107.4% upside | |
| 2024-03-13 | Morgan StanleyMatthew Harrison | $1,115 | 94.5% upside | |
| 2024-01-12 | BMO CapitalBrian Abrahams | $1,076 | 87.7% upside | |
| 2024-01-12 | RBC CapitalBrian Abrahams | $1,076 | 87.7% upside | |
| 2023-03-27 | Leerink PartnersAndrew Berens | $976 | 70.2% upside | |
| 2023-03-24 | JefferiesAkash Tewari | $925 | 61.3% upside | |
| 2023-02-08 | EF Hutton | $853 | 48.8% upside | |
| 2023-02-06 | RBC Capital | $787 | 37.3% upside | |
| 2023-02-06 | Morgan Stanley | $883 | 54% upside | |
| 2023-02-06 | Leerink Partners | $834 | 45.5% upside | |
| 2022-11-11 | Guggenheim | $915 | 59.6% upside | |
| 2022-10-03 | Goldman Sachs | $970 | 69.2% upside | |
| 2022-09-16 | Canaccord Genuity | $750 | 30.8% upside | |